Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forbion European Acquisition Corp.FRBNU · Entity 108709 | Director | December 09, 2021 | December 09, 2021 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | July 16, 2024 | July 19, 2024 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | June 11, 2026 | June 13, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forbion European Acquisition Corp.
Report date December 09, 2021 · Filed December 09, 2021
This filing explicitly reported no securities owned.
NewAmsterdam Pharma Co N.V.
Report date July 16, 2024 · Filed July 19, 2024
This filing explicitly reported no securities owned.
Vor Biopharma Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10 | Direct | 57,162 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 57,162 · Balance 57,162 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
enGene Therapeutics Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | 31,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 21:37 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000929638-26-002257 · form4.xml · derivative · entry 1 Joustra Wouter · CIK 0001897813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Shares · 31,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. Read SEC document |
| June 11, 2026 Filed Jun 13, 2026 00:41 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock option (right to buy) · Derivative | 57,162 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-269999 · ownership.xml · derivative · entry 1 Joustra Wouter · CIK 0001897813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,162 Underlying: Common stock · 57,162 shares Expires 2036-06-10 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 23:17 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0001897813-25-000010 · form4-12192025_111221.xml · derivative · entry 1 Joustra Wouter · CIK 0001897813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-12-17 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 22:39 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000929638-25-002251 · form4.xml · derivative · entry 1 Joustra Wouter · CIK 0001897813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2035-06-16 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:08 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000929638-24-002215 · form4.xml · derivative · entry 1 Joustra Wouter · CIK 0001897813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-06-15 F1 · derivative.exercise_date: This option vests at 1/3 on each of the first, second and third anniversaries of the date vesting commenced, which was May 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.